Crispr Therapeutics shares tumble after significant earnings miss
Azzurro Capital Inc., a ten percent owner of Travelzoo (NASDAQ:TZOO), sold 17,500 shares of common stock on July 28 and 29, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sale comes as the stock has declined nearly 49% year-to-date, though InvestingPro analysis suggests the shares are currently undervalued.
The sales, conducted in two separate transactions, totaled $186,600. On July 28, 7,500 shares were sold at prices ranging from $11.08 to $11.10, and on July 29, 10,000 shares were sold at prices ranging from $10.34 to $10.36.
Following the transactions, Azzurro Capital Inc. directly owns 4,045,196 shares of Travelzoo. Ralph Bartel and the Ralph Bartel 2005 Trust indirectly own these shares.
In other recent news, Travelzoo reported its second-quarter earnings for 2025, revealing a significant miss in earnings per share (EPS) compared to market expectations. The company posted an EPS of $0.12, which was below the anticipated $0.24, marking a 50% negative surprise for analysts. However, Travelzoo managed to exceed revenue expectations, reporting $23.9 million against the forecasted $23.39 million. Despite this revenue beat, the earnings miss has been a focal point for investors. The market’s reaction was immediate, reflecting concerns over the earnings performance. These developments are crucial for stakeholders evaluating the company’s financial health and future prospects. Analysts and investors are likely to keep a close watch on Travelzoo’s upcoming quarters for any signs of recovery or further challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.